Literature DB >> 15867347

Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk.

Makoto T Kimura1, Takahiro Mori, Jeffrey Conroy, Norma J Nowak, Susumu Satomi, Katsuyuki Tamai, Hiroki Nagase.   

Abstract

STK15/Aurora-A is a serine/threonine kinase essential for chromosome segregation and cytokinesis, and is considered to be a cancer susceptibility gene in mice and humans. Two coding single nucleotide polymorphisms in Aurora-A, 91T>A [phenylalanine/isoleucine (F/I)] and 169G>A [valine/isoleucine (V/I)], create four haplotypes, 91T-169G, 91A-169G, 91T-169A, and 91A-169A. We evaluated the association between these coding single nucleotide polymorphisms and esophageal cancer risk by genotyping 197 esophageal cancer cases and 146 controls. Haplotype 91A-169A (I31/I57) was observed to be statistically more frequent in cancer cases (odds ratio, 3.1452; 95% confidence interval, 1.0258-9.6435). Functional differences among the four isoforms were then analyzed to reveal the source of the cancer risk. Kinase activity levels of I31/I57 and F31/I57 were reduced to 15% and 40% compared with I31/V57 in vivo and in vitro. We considered the differences between the kinase activities and divided individuals into four categories of Aurora-A haplotype combination. Category I had 57.5% or less kinase activity compared with the most common category, category III, and had a significantly higher estimated cancer risk (odds ratio, 5.5328; 95% confidence interval, 1.8149-16.8671). Abnormal nuclear morphology, a characteristic of genomic instability, was observed to be 30 to 40 times more frequent in human immortalized fibroblast cells overexpressing I31/I57 or F31/I57 compared with the others. Furthermore, significantly higher levels of chromosomal instability were observed in cancers in category I (homozygote 91T-169A) than those in category III (homozygous 91A-169G). These results indicate that the less kinase active Aurora-A haplotype combinations might induce genomic instability and increase esophageal cancer risk either in a recessive or a dominant manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867347      PMCID: PMC2536656          DOI: 10.1158/0008-5472.CAN-04-2149

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing.

Authors:  A Alderborn; A Kristofferson; U Hammerling
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

2.  Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor.

Authors:  T Hori; A Takaori-Kondo; Y Kamikubo; T Uchiyama
Journal:  Oncogene       Date:  2000-06-22       Impact factor: 9.867

3.  A subset of skin tumor modifier loci determines survival time of tumor-bearing mice.

Authors:  H Nagase; J H Mao; A Balmain
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway.

Authors:  K Honda; H Mihara; Y Kato; A Yamaguchi; H Tanaka; H Yasuda; K Furukawa; T Urano
Journal:  Oncogene       Date:  2000-06-01       Impact factor: 9.867

5.  Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts.

Authors:  N Yabuta; T Fujii; N G Copeland; D J Gilbert; N A Jenkins; H Nishiguchi; Y Endo; S Toji; H Tanaka; Y Nishimune; H Nojima
Journal:  Genomics       Date:  2000-01-15       Impact factor: 5.736

6.  STK15 polymorphism and breast cancer risk in a population-based study.

Authors:  Kathleen M Egan; Polly A Newcomb; Christine B Ambrosone; Amy Trentham-Dietz; Linda Titus-Ernstoff; John M Hampton; Makoto T Kimura; Hiroki Nagase
Journal:  Carcinogenesis       Date:  2004-07-22       Impact factor: 4.944

Review 7.  Searching for cancer-associated gene polymorphisms: promises and obstacles.

Authors:  Evgeny N Imyanitov; Alexandr V Togo; Kaido P Hanson
Journal:  Cancer Lett       Date:  2004-02-10       Impact factor: 8.679

8.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.

Authors:  H Zhou; J Kuang; L Zhong; W L Kuo; J W Gray; A Sahin; B R Brinkley; S Sen
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

9.  The sequence of the human genome.

Authors:  J C Venter; M D Adams; E W Myers; P W Li; R J Mural; G G Sutton; H O Smith; M Yandell; C A Evans; R A Holt; J D Gocayne; P Amanatides; R M Ballew; D H Huson; J R Wortman; Q Zhang; C D Kodira; X H Zheng; L Chen; M Skupski; G Subramanian; P D Thomas; J Zhang; G L Gabor Miklos; C Nelson; S Broder; A G Clark; J Nadeau; V A McKusick; N Zinder; A J Levine; R J Roberts; M Simon; C Slayman; M Hunkapiller; R Bolanos; A Delcher; I Dew; D Fasulo; M Flanigan; L Florea; A Halpern; S Hannenhalli; S Kravitz; S Levy; C Mobarry; K Reinert; K Remington; J Abu-Threideh; E Beasley; K Biddick; V Bonazzi; R Brandon; M Cargill; I Chandramouliswaran; R Charlab; K Chaturvedi; Z Deng; V Di Francesco; P Dunn; K Eilbeck; C Evangelista; A E Gabrielian; W Gan; W Ge; F Gong; Z Gu; P Guan; T J Heiman; M E Higgins; R R Ji; Z Ke; K A Ketchum; Z Lai; Y Lei; Z Li; J Li; Y Liang; X Lin; F Lu; G V Merkulov; N Milshina; H M Moore; A K Naik; V A Narayan; B Neelam; D Nusskern; D B Rusch; S Salzberg; W Shao; B Shue; J Sun; Z Wang; A Wang; X Wang; J Wang; M Wei; R Wides; C Xiao; C Yan; A Yao; J Ye; M Zhan; W Zhang; H Zhang; Q Zhao; L Zheng; F Zhong; W Zhong; S Zhu; S Zhao; D Gilbert; S Baumhueter; G Spier; C Carter; A Cravchik; T Woodage; F Ali; H An; A Awe; D Baldwin; H Baden; M Barnstead; I Barrow; K Beeson; D Busam; A Carver; A Center; M L Cheng; L Curry; S Danaher; L Davenport; R Desilets; S Dietz; K Dodson; L Doup; S Ferriera; N Garg; A Gluecksmann; B Hart; J Haynes; C Haynes; C Heiner; S Hladun; D Hostin; J Houck; T Howland; C Ibegwam; J Johnson; F Kalush; L Kline; S Koduru; A Love; F Mann; D May; S McCawley; T McIntosh; I McMullen; M Moy; L Moy; B Murphy; K Nelson; C Pfannkoch; E Pratts; V Puri; H Qureshi; M Reardon; R Rodriguez; Y H Rogers; D Romblad; B Ruhfel; R Scott; C Sitter; M Smallwood; E Stewart; R Strong; E Suh; R Thomas; N N Tint; S Tse; C Vech; G Wang; J Wetter; S Williams; M Williams; S Windsor; E Winn-Deen; K Wolfe; J Zaveri; K Zaveri; J F Abril; R Guigó; M J Campbell; K V Sjolander; B Karlak; A Kejariwal; H Mi; B Lazareva; T Hatton; A Narechania; K Diemer; A Muruganujan; N Guo; S Sato; V Bafna; S Istrail; R Lippert; R Schwartz; B Walenz; S Yooseph; D Allen; A Basu; J Baxendale; L Blick; M Caminha; J Carnes-Stine; P Caulk; Y H Chiang; M Coyne; C Dahlke; A Deslattes Mays; M Dombroski; M Donnelly; D Ely; S Esparham; C Fosler; H Gire; S Glanowski; K Glasser; A Glodek; M Gorokhov; K Graham; B Gropman; M Harris; J Heil; S Henderson; J Hoover; D Jennings; C Jordan; J Jordan; J Kasha; L Kagan; C Kraft; A Levitsky; M Lewis; X Liu; J Lopez; D Ma; W Majoros; J McDaniel; S Murphy; M Newman; T Nguyen; N Nguyen; M Nodell; S Pan; J Peck; M Peterson; W Rowe; R Sanders; J Scott; M Simpson; T Smith; A Sprague; T Stockwell; R Turner; E Venter; M Wang; M Wen; D Wu; M Wu; A Xia; A Zandieh; X Zhu
Journal:  Science       Date:  2001-02-16       Impact factor: 47.728

10.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

View more
  23 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

2.  Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jun Qin; Xiao-Feng He; Wu Wei; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Hui-Qiang Si
Journal:  Mol Genet Genomics       Date:  2014-08-26       Impact factor: 3.291

3.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

4.  Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.

Authors:  Andrea Necchi; Giulia Pintarelli; Daniele Raggi; Patrizia Giannatempo; Francesca Colombo
Journal:  Invest New Drugs       Date:  2017-02-03       Impact factor: 3.850

5.  Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation.

Authors:  Jennifer Y Pan; Jaffer A Ajani; Jian Gu; Yubo Gong; Angel Qin; Angel Quin; Maosheng Hung; Xifeng Wu; Julie G Izzo
Journal:  Cancer       Date:  2011-12-27       Impact factor: 6.860

Review 6.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

7.  A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.

Authors:  Daniel Dauch; Ramona Rudalska; Giacomo Cossa; Jean-Charles Nault; Tae-Won Kang; Torsten Wuestefeld; Anja Hohmeyer; Sandrine Imbeaud; Tetyana Yevsa; Lisa Hoenicke; Tatu Pantsar; Przemyslaw Bozko; Nisar P Malek; Thomas Longerich; Stefan Laufer; Antti Poso; Jessica Zucman-Rossi; Martin Eilers; Lars Zender
Journal:  Nat Med       Date:  2016-05-23       Impact factor: 53.440

8.  Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.

Authors:  Christopher Ricketts; Maurice P Zeegers; Jan Lubinski; Eamonn R Maher
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

9.  Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China.

Authors:  Ying Gao; Nan Hu; XiaoYou Han; Carol Giffen; Ti Ding; Alisa Goldstein; Philip Taylor
Journal:  BMC Cancer       Date:  2009-08-05       Impact factor: 4.430

10.  A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing.

Authors:  Hiroshi Hongo; Takeo Kosaka; Seishi Nakatsuka; Mototsugu Oya
Journal:  Int Cancer Conf J       Date:  2021-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.